Start Date
September 30, 2013
Primary Completion Date
August 31, 2015
Study Completion Date
August 31, 2015
IMMU 130
This is a Phase II, open-label study of IMMU-130 administered every 14 days for a period of 24 weeks to patients with metastatic colorectal cancer who have been previously treated with at least one prior irinotecan-containing regimen.
Lead Sponsor
Gilead Sciences
INDUSTRY